Tu1093 EFFICACY OF MOSAPRIDE CITRATE WITH A SPLIT DOSE OF PEG PLUS ASCORBIC ACID FOR BOWEL PREPARATION IN ELDERLY PATIENTS: A RANDOMIZED CONTROLLED TRIAL

Abstract

Old age is a risk factor of suboptimal bowel preparation. This study aimed to evaluate the efficacy of mosapride citrate with a split dose of polyethylene glycol (PEG) plus ascorbic acid for bowel preparation in elderly patients (≥65 years). This prospective investigator-blinded randomized study was conducted from November 2017 to October 2018. Patients were randomly divided into two groups: mosapride citrate with split-dose PEG plus ascorbic acid (mosapride group) or split-dose PEG plus ascorbic acid alone (non-mosapride group). Mosapride citrate 15 mg (Gastin CR®) was administered once with each split-dose of the bowel preparation. Bowel preparation quality was assessed using the Boston Bowel Preparation Scale (BBPS). A total of 257 patients were finally included and analyzed. Total BBPS score was significantly higher in the mosapride group than in the non-mosapride group (8.53 vs 8.24, P = 0.033). The BBPS scores of the right colon and mid-colon were 2.75 vs 2.61 (P = 0.044) and 2.89 vs 2.79 (P = 0.030), respectively. The rate of adequate preparation (BBPS ≥6) was similar in both groups (98.4% vs 98.5%, P = 0.968), while the rate of excellent preparation (BBPS = 9) was higher in the mosapride group than in the non-mosapride group (73.8% vs 61.1%, P = 0.029). The total incidence of adverse events during administration of the bowel cleansing agent, particularly abdominal fullness, was lower in the mosapride group (11.9% vs 30.5%, P < 0.001). Mosapride citrate with a split-dose of PEG plus ascorbic acid in elderly patients showed bowel preparation efficacy and reduced adverse events such as abdominal fullness during administration of the bowel cleansing agent.